Recent Advances in the Treatment of Moderate-to-Severe Psoriasis: A Focus on Targeted Agents

Recent Advances in the Treatment of Moderate-to-Severe Psoriasis: A Focus on Targeted Agents

On-Demand Webcast

Joel M. Gelfand, MD, MSCE
Professor of Dermatology and Epidemiology
Vice Chair for Clinical Research
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Intended Learners

This activity is designed for dermatologists, rheumatologists, gastroenterologists, immunologists, nurse practitioners, nurses, physician assistants, pharmacists and other healthcare professionals involved in the management of patients with autoimmune diseases.

Learning Objectives

After completing this activity, participants should be able to:

  • Characterize the challenges in the treatment of patients with moderate-to-severe PSO that lead to suboptimal outcomes
  • Describe the role of IL-23/Th17 signaling pathways in the pathogenesis of PSO and the benefits of targeting upstream pro-inflammatory cytokines in the immunologic cascade
  • Evaluate the clinical data surrounding the efficacy, safety, mechanisms of action, onset/duration of action, and dosing of new and emerging IL-23 inhibitors for the treatment of moderate-to-severe PSO
  • Incorporate IL-23 inhibitors into treatment plans for patients with moderate-to-severe PSO
Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at, participants may immediately print their documentation of credit.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Participants who have successfully completed the live version of this activity (IAS 2018; April 27-29, 2018) are not eligible to receive credit for this enduring webcast.

Release date: June 29, 2018
Expiration date: June 29, 2019
Estimated time to complete: .5 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Jointly Accredited ProviderIn support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards .5 contact hour.


This activity is approved for .50 contact hour (0.075 CEU) of continuing pharmacy education (UAN JA0006201-0000-18-104-H01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation and Compliance, NACCME, in writing at 104 Windsor Center Drive, Suite 200, East Windsor, NJ 08520. The Senior Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer:  Joseph C. English, III, MD, Professor of Dermatology, University of Pittsburgh, Department of Dermatology, Pittsburgh, Pennsylvania

Nurse Planner:  Susie Seaman, NP, Sharp Rees-Stealy Wound Clinic, San Diego, California

Planning Committee

The planning committee comprises Joseph  C. English, III, MD, Joel Gelfand, MD, MSCE, Susie Seaman, NP; Donna Brophy, Jennifer Browne, Molly, Duda, Mary Johnson, Jennifer Ilycn, Mike Kearney, Todd Kunkler, and Randy Robbin, NACCME; and Nicola Sirdevan and Susan Yarbrough, IMEDEX.  

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Gelfand: Consultant-Coherus BioSciences, Dr. Reddy's Labs, Dermira, Janssen Biologics, Merck (DSMB), Novartis Corp, Pfizer, Regeneron, Sanofi; Honoraria/Research Grants (to the Trustees of the University of Pennsylvania)-AbbVie, Celgene, Janssen, Novartis, Regeneron, Sanofi, Pfizer; Co-Patent Holder-Resiquimod for treatment of cutaneous T cell lymphoma

Ms. Seaman:  Advisory Board—Mölnlycke

Dr. English has disclosed no relevant financial relationships with any commercial interests.

Ms. Brophy, Ms. Browne, Ms. Duda, Ms. Johnson, Ms. Ilycn, Mr. Kearney, Mr. Kunkler, and Mr. Robbin, NACCME, have disclosed no relevant financial relationships with any commercial interests.  Ms. Sirdevan, and Ms. Yarbrough, IMEDEX, have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty members have disclosed that off-label/unapproved uses of drugs and/or devices will be discussed: 

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

Supported by educational grants from AbbVie, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.